Literature DB >> 28285172

Multifunctional LUV liposomes decorated for BBB and amyloid targeting - B. In vivo brain targeting potential in wild-type and APP/PS1 mice.

Konstantina Papadia1, Anastasios D Giannou2, Eleni Markoutsa1, Christian Bigot3, Greejte Vanhoute3, Spyridon Mourtas1, Annemie Van der Linded3, Georgios T Stathopoulos4, Sophia G Antimisiaris5.   

Abstract

Multifunctional liposomes (mf-LIPs) having a curcumin-lipid ligand (to target amyloids) together with two ligands to target the transferrin, and the low-density apolipoprotein receptor of the blood-brain-barrier (BBB) on their surface, were previously studied (in vitro) as potential theranostic systems for Alzheimer's disease (AD) (Papadia et al., 2017, Eur. J. Pharm. Sciences; 101:140-148). Herein, the targeting potential of mf-LIPs was compared to that of BBB-LIPs (liposomes having only the two BBB-specific ligands) in FVB mice (normal), as well as in double transgenic mice (APP/PS1) and their corresponding littermates (WT), by live-animal (in vivo) and explanted organ (ex vivo) imaging. In FVB mice, the head-signals of mf-LIPs and BBB-LIPs are either similar, or signals from mf-LIP are higher, suggesting that the co-presence of the curcumin derivative on the liposome surface does not disturb the functionality of the BBB-specific ligands. Higher brain/liver+spleen ratios (ex vivo) were calculated post-injection of mf-LIP, compared to those found after BBB-LIP injection, due to the reduced distribution of mf-LIPs in the liver and spleen; showing that the curcumin ligand increases the stealth properties of liposomes by reducing their uptake by liver and spleen. The later effect is more pronounced when the density of the BBB-specific ligands on the mf-LIPs is 0.1mol%, compared to 0.2%, highlighting the importance of this parameter. When a high lipid dose (4mg/mouse) is injected in WT and APP/PS1 mice, the head-signals of mf-LIPs are significantly higher than those of BBB-LIPs, but no differences are observed between WT and APP/PS1 mice. However, after administration of a low liposome dose (0.05mg/mouse) of mf-LIPs, significant differences in the head-signals are found between WT and transgenic mice, highlighting the AD theranostic potential of the multifunctional liposomes, as well as the importance of the experimental parameters used in such in vivo screening studies.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain; Curcumin; Liposome; Live imaging; Multifunctional; Nanoparticle

Mesh:

Substances:

Year:  2017        PMID: 28285172     DOI: 10.1016/j.ejps.2017.03.010

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  8 in total

Review 1.  Pathogenic mechanisms and therapeutic promise of phytochemicals and nanocarriers based drug delivery against radiotherapy-induced neurotoxic manifestations.

Authors:  Ashif Iqubal; Mohammad Kashif Iqubal; Sumit Sharma; Mohd Wasim; Mohamed A Alfaleh; Shadab Md; Sanjula Baboota; Javed Ali; Syed Ehtaishamul Haque
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 2.  Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future Opportunities.

Authors:  Muhammad Ovais; Nashmia Zia; Irshad Ahmad; Ali Talha Khalil; Abida Raza; Muhammad Ayaz; Abdul Sadiq; Farhat Ullah; Zabta Khan Shinwari
Journal:  Front Aging Neurosci       Date:  2018-10-23       Impact factor: 5.750

3.  Transferrin-Modified Osthole PEGylated Liposomes Travel the Blood-Brain Barrier and Mitigate Alzheimer's Disease-Related Pathology in APP/PS-1 Mice.

Authors:  Liang Kong; Xue-Tao Li; Ying-Nan Ni; Hong-He Xiao; Ying-Jia Yao; Yuan-Yuan Wang; Rui-Jun Ju; Hong-Yan Li; Jing-Jing Liu; Min Fu; Yu-Tong Wu; Jing-Xian Yang; Lan Cheng
Journal:  Int J Nanomedicine       Date:  2020-04-23

Review 4.  Nanomedicines in the Management of Alzheimer's Disease: Current View and Future Prospects.

Authors:  Hitesh Chopra; Shabana Bibi; Inderbir Singh; Mohammad Amjad Kamal; Fahadul Islam; Fahad A Alhumaydhi; Talha Bin Emran; Simona Cavalu
Journal:  Front Aging Neurosci       Date:  2022-07-08       Impact factor: 5.702

5.  Preparation, Physicochemical Properties, and In Vitro Toxicity towards Cancer Cells of Novel Types of Arsonoliposomes.

Authors:  Paraskevi Zagana; Spyridon Mourtas; Anastasia Basta; Sophia G Antimisiaris
Journal:  Pharmaceutics       Date:  2020-04-06       Impact factor: 6.321

6.  Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma.

Authors:  Shuangming Kang; Wenjuan Duan; Shangqian Zhang; Dawei Chen; Jianfang Feng; Na Qi
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

Review 7.  The Role of Natural Compounds and their Nanocarriers in the Treatment of CNS Inflammation.

Authors:  Bikram Khadka; Jae-Young Lee; Dong Ho Park; Ki-Taek Kim; Jong-Sup Bae
Journal:  Biomolecules       Date:  2020-10-01

Review 8.  Curcumin Formulations and Trials: What's New in Neurological Diseases.

Authors:  Stella Gagliardi; Carlo Morasso; Polychronis Stivaktakis; Cecilia Pandini; Veronica Tinelli; Aristides Tsatsakis; Davide Prosperi; Miriam Hickey; Fabio Corsi; Cristina Cereda
Journal:  Molecules       Date:  2020-11-18       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.